150K cells

Phase 2

EEmmecell

150K cells is one of 3 therapeutic programs targeting Corneal Edema. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Corneal EdemaNot yet recruiting

Corneal EdemaPhase 2

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Corneal Edema

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Kenalog

150K cells

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Corneal Edema

NCT07729137

Clinical

Trials by Indication[1]

Corneal Edema1 trial

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)

Not yet recruiting·EEmmecell·Phase 2·NCT07729137·121 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 150K cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 150K cells. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Emmecell company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: EEmmecell

150K cells

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Corneal Edema1 trial

References

Drug Info

Quick Facts

Related News